Pharmacokinetics of Amikacin after Intravenous Intramuscular and Subcutaneous Administration in German Shepherd Dog

The purpose of the study was to compare the pharmacokinetics of amikacin in German Shepherd dogs following single intravenous intramuscular and subcutaneous injections. Amikacin was administrated by a randomized three cross-over design after single intravenous (10 mg kg(-1)) intramuscular (10 mg kg(-1)) and subcutaneous injections (10 mg kg(-1)) in 9 healthy German Shepherd dogs. The concentrations of Amikacin in plasma were determined by LC-MS/MS and the concentration-time data were analyzed with 3 p97 program. It's best to fit the amikacin concentration-time data to two-compartment open model after single iv. dosing. The main pharmacokinetic parameters were as follows: T-1/2 beta = (1.61 +/- 0.07)h, V-c = (0.10 +/- 0.01) L kg(-1), CL(s) = (0.08 +/- 0.01) 1 kg(-1) h, AUC = (129.15 +/- 6.74) mu g mL(-1) h. A two-compartment model with first order absorption best described the drug concentration-time data after single i.m. and s.c. in healthy dogs. The main plaarmacokinetic parameters were as follows: T-1/2 alpha = (0,49 +/- 0,07) h and (0,64 +/- 0,08) h, respectively; T-1/2 beta (1.40 +/- 0.12) h and (1.78 +/- 0.15) h, respectively; T-peak = (0.79 +/- 0.09) h and (0.89 +/- 0.07) h, respectively; C-max = (44.59 +/- 2.10) mu g mL(-1) and (31.42 +/- 1.39) mu g mL(-1), respectively; F = (91.3 +/- 6.6) and (81.0 +/- 5.6)%, respectively.